Protalix BioTherapeutics (PLX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Protalix BioTherapeutics (PLX) over the last 15 years, with Q4 2024 value amounting to $35.7 million.
- Protalix BioTherapeutics' Accumulated Depreciation & Amortization rose 302.99% to $35.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $35.7 million, marking a year-over-year increase of 302.99%. This contributed to the annual value of $35.7 million for FY2024, which is 302.99% up from last year.
- Latest data reveals that Protalix BioTherapeutics reported Accumulated Depreciation & Amortization of $35.7 million as of Q4 2024, which was up 302.99% from $34.7 million recorded in Q4 2023.
- In the past 5 years, Protalix BioTherapeutics' Accumulated Depreciation & Amortization registered a high of $35.7 million during Q4 2024, and its lowest value of $31.9 million during Q4 2020.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $33.7 million (2022), whereas its average is $33.8 million.
- In the last 5 years, Protalix BioTherapeutics' Accumulated Depreciation & Amortization surged by 397.02% in 2020 and then skyrocketed by 259.69% in 2021.
- Protalix BioTherapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $31.9 million in 2020, then grew by 2.6% to $32.8 million in 2021, then grew by 2.85% to $33.7 million in 2022, then grew by 2.97% to $34.7 million in 2023, then rose by 3.03% to $35.7 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $35.7 million for Q4 2024, versus $34.7 million for Q4 2023 and $33.7 million for Q4 2022.